Ali M. Saeed

Ali M. Saeed

Auto-generated profile, based on publicly available information

Ali M. Saeed

Convergence Institute, Johns Hopkins University, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
ASAli M. Saeed
Ali M. Saeed
RKRahul Khairnar
Rahul Khairnar
ASAnkur M. Sharma
Ankur M. Sharma
GLGary L. Larson
Gary L. Larson
HTHenry K. Tsai
Henry K. Tsai
MMMark V. Mishra
Mark V. Mishra
As a means of limiting normal tissue toxicity, proton-beam therapy (PBT) is an emerging radiation modality for glioblastoma (GBM) reirradiation. However, data for recurrent GBM treated with PBT reirradiation is limited. Therefore, we analyzed treatment patterns, toxicities, and clinical outcomes of patients with recurrent GBM treated with PBT reirradiation using the multi-institutional Proton Collaborative Group registry. Prospectively collected data for patients with recurrent GBM who underwent PBT while enrolled in Proton Collaborative Group study 01-009 (NCT01255748) were analyzed. We evaluated overall survival (OS), progression-free survival (PFS), and toxicity. Toxicities were scored per the Common Terminology Criteria for Adverse Events, version 4.0. Descriptive statistics were used to report patient, tumor, and treatment characteristics. Multivariable analyses (MVA) for toxicity were conducted using logistic regression. The Kaplan-Meier method was used to calculate OS and PFS. MVA for OS and PFS was conducted using Cox proportional-hazards models. The SAS statistical software was used for the analysis. We identified 45 recurrent patients with GBM who underwent PBT reirradiation between 2012 and 2018. The median time between initial GBM diagnosis and recurrence was 20.2 months. The median follow-up time from PBT reirradiation was 10.7 months. Median PFS was 13.9 months (95% confidence interval [CI], 8.23-20.0 months) and median OS was 14.2 months (95% CI, 9.6-16.9 months) after PBT reirradiation. One patient experienced an acute grade 3 toxicity, 4 patients experienced late grade 3 toxicity (no grade ≥4 toxicities). MVA revealed that prior surgery was associated with a 91.3% decreased hazard of death (hazard ratio: 0.087; 95% CI, 0.02-0.42; P < .01). No explanatory variables were associated with PFS or grade 3 toxicities. This is the largest series to date reporting outcomes for PBT reirradiation of patients with recurrent GBM. Our analysis indicates that PBT is well tolerated and offers efficacy rates comparable with previously reported photon reirradiation.

1 December 2024 in Cancer Research Communications
Verified
Journal Article
Open access
TPTheron Palmer
Theron Palmer
MKMichael D. Kessler
Michael D. Kessler
XSXiaoshan M. Shao
Xiaoshan M. Shao
ABArchana Balan
Archana Balan
MYMark Yarchoan
Mark Yarchoan
LDLudmila Danilova
Ludmila Danilova
Aberrant alternative splicing can generate neoantigens, which can themselves stimulate immune responses and surveillance. Previous methods for quantifying splicing-derived neoantigens are limited by independent references and potential batch effects. Here, we introduce SpliceMutr, a bioinformatics approach and pipeline for identifying splicing-derived neoantigens from tumor and normal data. SpliceMutr facilitates the identification of tumor-specific antigenic splice variants, predicts MHC-binding affinity, and estimates splicing antigenicity scores per gene. By applying this tool to transcriptomic data from The Cancer Genome Atlas, we generate splicing-derived neoantigens and neoantigenicity scores per sample and across all cancer types and find numerous correlations between splicing antigenicity and well-established biomarkers of antitumor immunity. Notably, carriers of mutations within splicing machinery genes have higher splicing antigenicity, which provides support for our approach. Further analysis of splicing antigenicity in cohorts of patients with melanoma treated with mono- or combined immune checkpoint inhibition suggests that the abundance of splicing antigens is reduced post-treatment from baseline in patients who progress. We also observe increased splicing antigenicity in responders to immunotherapy, which may relate to an increased capacity to mount an immune response to splicing-derived antigens. We find the splicing antigenicity to be higher in tumor samples when compared with normal, that mutations in the splicing machinery result in increased splicing antigenicity in some cancers, and higher splicing antigenicity is associated with positive response to immune checkpoint inhibitor therapies. Furthermore, this new computational pipeline provides novel analytical capabilities for splicing antigenicity and is openly available for further immuno-oncology analysis. Significance: SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load of some The Cancer Genome Atlas cancer subtypes. Future studies of the relationship between splicing antigenicity and immune checkpoint inhibitor response pan-cancer are essential to establish the interplay between antigen heterogeneity and immunotherapy regimen on patient response.

13 May 2025
Verified
Other
Open access
TPTheron Palmer
Theron Palmer
MKMichael D. Kessler
Michael D. Kessler
XSXiaoshan M. Shao
Xiaoshan M. Shao
ABArchana Balan
Archana Balan
MYMark Yarchoan
Mark Yarchoan
LDLudmila Danilova
Ludmila Danilova
The supplementary figures file

3 April 2025
Verified
Other
Open access
TPTheron Palmer
Theron Palmer
MKMichael D. Kessler
Michael D. Kessler
XSXiaoshan M. Shao
Xiaoshan M. Shao
ABArchana Balan
Archana Balan
MYMark Yarchoan
Mark Yarchoan
LDLudmila Danilova
Ludmila Danilova
The supplementary figures file

13 May 2025
Verified
Other
Open access
TPTheron Palmer
Theron Palmer
MKMichael D. Kessler
Michael D. Kessler
XSXiaoshan M. Shao
Xiaoshan M. Shao
ABArchana Balan
Archana Balan
MYMark Yarchoan
Mark Yarchoan
LDLudmila Danilova
Ludmila Danilova
Supplementary Table S2. Splicing antigenicity differences between samples with mutated and samples without mutated splicing factor genes. The splicing antigenicity differences between samples with mutated and non-mutated splicing factors for all 119 chosen splicing factor genes and for each TCGA cancer subtype.

16 December 2024
Verified
Other
Open access
TPTheron Palmer
Theron Palmer
MKMichael D. Kessler
Michael D. Kessler
XSXiaoshan M. Shao
Xiaoshan M. Shao
ABArchana Balan
Archana Balan
MYMark Yarchoan
Mark Yarchoan
LDLudmila Danilova
Ludmila Danilova
Pan-cancer correlation analysis of per-sample SA with nonsilent mutations in splicing machinery coding genes. Distribution of SA per sample, averaged across genes, by mutations in the splicing factor gene SF3B1 in BRCA (A) or HNSC (B). *, P value ≤ 0.05. See TCGA cancer-type abbreviations in Supplementary Table S1. SA, splicing antigenicity.